Published in Dig Liver Dis on July 15, 2010
The transjugular intrahepatic portosystemic shunt in the treatment of portal hypertension: current status. Int J Hepatol (2012) 1.00
Transjugular intrahepatic portosystemic shunt for portal cavernoma with symptomatic portal hypertension in non-cirrhotic patients. Dig Dis Sci (2011) 0.96
Portal vein thrombosis. J Clin Exp Hepatol (2015) 0.92
Selection of a TIPS stent for management of portal hypertension in liver cirrhosis: an evidence-based review. World J Gastroenterol (2014) 0.89
Therapy Algorithm for Portal Vein Thrombosis in Liver Cirrhosis: The Internist's Point of View. Viszeralmedizin (2014) 0.87
Clinical Management of Chronic Portal/Mesenteric Vein Thrombosis: The Surgeon's Point of View. Viszeralmedizin (2014) 0.86
Clinical outcome and predictors of survival after TIPS insertion in patients with liver cirrhosis. World J Gastroenterol (2012) 0.86
Efficacy of covered and bare stent in TIPS for cirrhotic portal hypertension: A single-center randomized trial. Sci Rep (2016) 0.77
Transjugular intrahepatic portosystemic shunt for the treatment of portal hypertension in noncirrhotic patients with portal cavernoma. Gastroenterol Res Pract (2014) 0.77
Safety of supramesocolic surgery in patients with portal cavernoma without portal vein decompression. Large single centre experience. HPB (Oxford) (2016) 0.75
The Evolution of Transjugular Intrahepatic Portosystemic Shunt: Tips. ISRN Hepatol (2014) 0.75
Randomized controlled study of TIPS versus paracentesis plus albumin in cirrhosis with severe ascites. Hepatology (2004) 3.22
Incidence and natural history of small esophageal varices in cirrhotic patients. J Hepatol (2003) 2.46
Validation of automated blood cell counter for the determination of polymorphonuclear cell count in the ascitic fluid of cirrhotic patients with or without spontaneous bacterial peritonitis. Am J Gastroenterol (2003) 2.31
Nutritional supplementation with branched-chain amino acids in advanced cirrhosis: a double-blind, randomized trial. Gastroenterology (2003) 2.31
Cognitive dysfunction is associated with poor socioeconomic status in patients with cirrhosis: an international multicenter study. Clin Gastroenterol Hepatol (2013) 2.14
Glaucoma and Helicobacter pylori: eyes wide shut? Dig Liver Dis (2012) 2.10
NADPH oxidase-mediated platelet isoprostane over-production in cirrhotic patients: implication for platelet activation. Liver Int (2011) 2.09
The chronic use of beta-blockers and proton pump inhibitors may affect the rate of bacterial infections in cirrhosis. Liver Int (2014) 2.07
Evidence of persistent cognitive impairment after resolution of overt hepatic encephalopathy. Clin Gastroenterol Hepatol (2010) 2.01
A randomized study on Peg-interferon alfa-2a with or without ribavirin in liver transplant recipients with recurrent hepatitis C. J Hepatol (2007) 1.83
Lower limb multilevel treatment with drug-eluting balloons: 6-month results from the DEBELLUM randomized trial. J Endovasc Ther (2012) 1.68
Glial fibrillary acidic protein as an early marker of hepatic stellate cell activation in chronic and posttransplant recurrent hepatitis C. Liver Transpl (2008) 1.65
Retrograde popliteal access in the supine patient for recanalization of the superficial femoral artery: initial results. J Endovasc Ther (2011) 1.64
Cirrhotic patients are at risk for health care-associated bacterial infections. Clin Gastroenterol Hepatol (2010) 1.63
Iron reduction and sustained response to interferon-alpha therapy in patients with chronic hepatitis C: results of an Italian multicenter randomized study. Am J Gastroenterol (2002) 1.62
Drug therapy: rifaximin. Hepatology (2010) 1.60
Kupffer cells are activated in cirrhotic portal hypertension and not normalised by TIPS. Gut (2011) 1.52
MELD score is better than Child-Pugh score in predicting 3-month survival of patients undergoing transjugular intrahepatic portosystemic shunt. J Hepatol (2002) 1.51
Heritability of central blood pressure and arterial stiffness: a twin study. J Hypertens (2012) 1.45
Incidence, natural history, and risk factors of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt with polytetrafluoroethylene-covered stent grafts. Am J Gastroenterol (2008) 1.42
Sarcopenia in liver cirrhosis: the role of computed tomography scan for the assessment of muscle mass compared with dual-energy X-ray absorptiometry and anthropometry. Eur J Gastroenterol Hepatol (2015) 1.41
Is faecal-immunochemical test useful in patients with iron deficiency anaemia and without overt bleeding? Dig Liver Dis (2011) 1.38
High prevalence of spontaneous portal-systemic shunts in persistent hepatic encephalopathy: a case-control study. Hepatology (2005) 1.29
Efficacy of current guidelines for the treatment of spontaneous bacterial peritonitis in the clinical practice. World J Gastroenterol (2008) 1.26
Nutritional status: its influence on the outcome of patients undergoing liver transplantation. Liver Int (2009) 1.23
Hepatocellular carcinoma: role of unenhanced and delayed phase multi-detector row helical CT in patients with cirrhosis. Radiology (2005) 1.23
Polytetrafluoroethylene-covered nitinol stent-graft for transjugular intrahepatic portosystemic shunt creation: 3-year experience. Radiology (2004) 1.23
Hepatic encephalopathy after transjugular intrahepatic portosystemic shunt. Clin Liver Dis (2012) 1.20
Intracellular pathways mediating estrogen-induced cholangiocyte proliferation in the rat. Hepatology (2002) 1.15
Improving the inhibitory control task to detect minimal hepatic encephalopathy. Gastroenterology (2010) 1.14
The intrahepatic biliary epithelium is a target of the growth hormone/insulin-like growth factor 1 axis. J Hepatol (2005) 1.12
Polytetrafluoroethylene-covered stent grafts for TIPS procedure: 1-year patency and clinical results. Am J Gastroenterol (2004) 1.06
Sequential, concomitant and hybrid first-line therapies for Helicobacter pylori eradication: a prospective randomized study. J Med Microbiol (2014) 1.04
GFAP expression in the liver as an early marker of stellate cells activation. Ital J Anat Embryol (2006) 1.02
New ePTFE/FEP-covered stent in the palliative treatment of malignant biliary obstruction. J Vasc Interv Radiol (2002) 1.02
Malignant biliary obstruction: treatment with ePTFE-FEP- covered endoprostheses initial technical and clinical experiences in a multicenter trial. Radiology (2002) 1.02
Emerging issues in the use of transjugular intrahepatic portosystemic shunt (TIPS) for management of portal hypertension: time to update the guidelines? Dig Liver Dis (2009) 1.00
Standard triple and sequential therapies for Helicobacter pylori eradication: an update. Eur J Intern Med (2012) 0.99
Endoscopic screening for esophageal varices in cirrhotic patients. Hepatology (2002) 0.99
Muscle depletion increases the risk of overt and minimal hepatic encephalopathy: results of a prospective study. Metab Brain Dis (2012) 0.99
The natural history of portal hypertensive gastropathy in patients with liver cirrhosis and mild portal hypertension. Am J Gastroenterol (2004) 0.97
Clinical efficacy of transjugular intrahepatic portosystemic shunt created with covered stents with different diameters: results of a randomized controlled trial. J Hepatol (2010) 0.97
Cholestasis induced by total parenteral nutrition. Clin Liver Dis (2008) 0.96
Hepatocellular carcinoma: detection with triple-phase multi-detector row helical CT in patients with chronic hepatitis. Radiology (2003) 0.96
Malnutrition is a risk factor in cirrhotic patients undergoing surgery. Nutrition (2002) 0.96
Cardiac dysfunction in cirrhosis is not associated with the severity of liver disease. Eur J Intern Med (2012) 0.95
Depression, anxiety and alexithymia symptoms are major determinants of health related quality of life (HRQoL) in cirrhotic patients. Metab Brain Dis (2013) 0.94
Peripheral and splanchnic indole and oxindole levels in cirrhotic patients: a study on the pathophysiology of hepatic encephalopathy. Am J Gastroenterol (2010) 0.94
Comparison of changes in lipid profile after bilio-intestinal bypass and gastric banding in patients with morbid obesity. Obes Surg (2005) 0.93
Modifications of cardiac function in cirrhotic patients treated with transjugular intrahepatic portosystemic shunt (TIPS). Am J Gastroenterol (2002) 0.93
Appropriateness of the indication for colonoscopy: is the endoscopist the 'gold standard'? J Clin Gastroenterol (2012) 0.93
QT interval in patients with non-cirrhotic portal hypertension and in cirrhotic patients treated with transjugular intrahepatic porto-systemic shunt. J Hepatol (2003) 0.92